Boundless Bio, Inc.(BOLD) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, August 5, 2025 – Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology ...